Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

Morgan Stanley Adjusted Its 2011, 2013 EPS Estimates For Lexicon Pharmaceuticals

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
20 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Aug 12, 2011

Morgan Stanley adjusted its 2011 and 2013 EPS estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX) and maintained its equal-weight rating and $2 price target.

The bank sees a 2011 loss of $0.32 per share, narrower than its previous estimate for a loss of $0.34 per share, and a 2013 loss of $0.29 per share, narrower than its previous estimate for a loss of $0.30 per share.

Lexicon Pharmaceuticals has a potential upside of 129% based on a current price of $1.31 and an average consensus analyst price target of $3.

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more